The GLP‑1 Gray Market Is Collapsing in Public—But the Real Risk Isn’t ‘Fake Ozempic,’ It’s the Ingredient Switch You’ll Never See on the Label
As FDA enforcement tightens, “copycat” access doesn’t disappear—it morphs into euphemisms, additives, and quieter sourcing changes. The danger isn’t only counterfeits; it’s ambiguity you can’t audit once it’s in the vial.
By TheMurrow Editorial
April 15, 2026
Key Points
- 1Track the crackdown: FDA tightened shortage-era loopholes, shrinking mass “copycat” GLP‑1 compounding and pushing sellers toward murkier workarounds.
- 2Distinguish the risks: counterfeits impersonate brands, but the bigger everyday danger is hidden ingredient switching and unverifiable sourcing.
- 3Demand proof: ask for ingredient, concentration, dispensing pharmacy, and dosing education—especially when products come in vials or claim “equivalence.”
The most telling detail in America’s GLP‑1 boom isn’t the celebrity “Ozempic face” chatter or the breathless before‑and‑after photos. It’s the paperwork. In 2025, as national supply began to stabilize, the Food and Drug Administration started tightening the narrow lanes that had allowed a sprawling shadow economy of semaglutide and tirzepatide to flourish.
That shadow economy—often called the GLP‑1 gray market—isn’t one thing. It’s not just counterfeit pens with fake labels. It’s also a looser, more plausibly deniable ecosystem: compounding-adjacent clinics, telehealth bundles that promise “custom” formulations, and “research use only” vials sold online to ordinary consumers who were never supposed to be the customer.
The crackdown has a predictable effect. When a regulatory door closes, the business model doesn’t vanish; it mutates. As mass-compounded “copycat” GLP‑1 access narrows, sellers look for workarounds: different dosage forms, added ingredients, “personalization,” or new peptides with less name recognition—and, for patients, less clarity.
“The gray market isn’t only counterfeit pens. It’s also ingredient substitution and sourcing decisions hidden from patients.”
— — TheMurrow Editorial
The GLP‑1 gray market: two ecosystems hiding in plain sight
The term “gray market” often implies a single underground pipeline. The GLP‑1 version is messier. During the demand surge of 2022–2024, and then during the enforcement squeeze that followed, two overlapping ecosystems took shape.
Compounding during constrained supply
One ecosystem is the traditional world of drug compounding: 503A pharmacies that prepare patient-specific prescriptions and 503B outsourcing facilities that can produce larger quantities for health care settings. Compounding can play a legitimate role when an FDA‑approved drug is not available or a patient has a specific clinical need (for example, a dose or formulation not offered commercially).
The FDA has been explicit about the boundary: compounded drugs are not FDA‑approved and do not undergo FDA premarket review for safety, quality, or effectiveness. The agency has also warned about dosing problems tied to compounded formulations, especially when patients or clinicians misunderstand concentration and volume. (FDA alerts and safety communications have repeatedly stressed this point.)
Source: FDA alerts on dosing errors associated with compounded GLP‑1 drugs (fda.gov).
The FDA has been explicit about the boundary: compounded drugs are not FDA‑approved and do not undergo FDA premarket review for safety, quality, or effectiveness. The agency has also warned about dosing problems tied to compounded formulations, especially when patients or clinicians misunderstand concentration and volume. (FDA alerts and safety communications have repeatedly stressed this point.)
Source: FDA alerts on dosing errors associated with compounded GLP‑1 drugs (fda.gov).
The compounding-adjacent economy
The second ecosystem is more opaque: online sellers and clinics offering semaglutide or tirzepatide as:
- “Research use only” powders or vials marketed direct-to-consumer
- Med-spa injections described as “Ozempic/Wegovy-like”
- Telehealth memberships that bundle “custom GLP‑1s,” sometimes with additives like B12
Some of these businesses are not simply compounding a medication after a clinician visit. They are marketing a product category. Patients may hear “compounded” and assume “regulated,” even when the sourcing, testing, and labeling look nothing like a conventional pharmacy supply chain.
- “Research use only” powders or vials marketed direct-to-consumer
- Med-spa injections described as “Ozempic/Wegovy-like”
- Telehealth memberships that bundle “custom GLP‑1s,” sometimes with additives like B12
Some of these businesses are not simply compounding a medication after a clinician visit. They are marketing a product category. Patients may hear “compounded” and assume “regulated,” even when the sourcing, testing, and labeling look nothing like a conventional pharmacy supply chain.
“When demand outpaces supply, consumers don’t stop wanting the drug—they start accepting ambiguity.”
— — TheMurrow Editorial
The policy turning point: shortage status and the shrinking legal runway
For several years, the shortage narrative functioned as a kind of permission slip. When supply constraints were acute, compounding expanded to meet demand. As supply improved, the FDA began clarifying what would—and would not—be tolerated.
A date-driven wind-down
In an FDA update on GLP‑1 policy as national supply began to stabilize, the agency addressed how enforcement would change as shortages were resolved. Two details matter for patients trying to understand why access is shifting.
- The FDA stated that tirzepatide injection shortage was resolved, and outlined an enforcement posture consistent with stabilized supply.
- For semaglutide injection products, the FDA described a phase-out approach:
- 503A enforcement discretion ended (the agency indicated it “has ended” for 503A in the period discussed).
- 503B enforcement discretion extended until May 22, 2025, after which the FDA could take enforcement action tied to shortage-based conditions.
Those aren’t abstract distinctions. They determine whether a high-volume “copycat” operation can plausibly claim it’s filling a temporary public health gap—or whether it is effectively manufacturing a version of a branded drug without the legal justification that shortages once supplied.
Source: FDA statement clarifying policies as national GLP‑1 supply begins to stabilize (fda.gov).
- The FDA stated that tirzepatide injection shortage was resolved, and outlined an enforcement posture consistent with stabilized supply.
- For semaglutide injection products, the FDA described a phase-out approach:
- 503A enforcement discretion ended (the agency indicated it “has ended” for 503A in the period discussed).
- 503B enforcement discretion extended until May 22, 2025, after which the FDA could take enforcement action tied to shortage-based conditions.
Those aren’t abstract distinctions. They determine whether a high-volume “copycat” operation can plausibly claim it’s filling a temporary public health gap—or whether it is effectively manufacturing a version of a branded drug without the legal justification that shortages once supplied.
Source: FDA statement clarifying policies as national GLP‑1 supply begins to stabilize (fda.gov).
What it means for patients in practice
As the runway shrinks, the business models that relied on mass availability have to change. In many cases, that means one of three pivots:
- narrowing to patient-specific, documented medical necessity scenarios
- switching marketing language toward “custom” blends or alternate forms
- drifting toward the less-policed edges of the internet (“research” peptides)
None of these moves automatically makes a product unsafe. The point is simpler: patients should expect more variability in what they are being offered—and more pressure to accept less transparency.
- narrowing to patient-specific, documented medical necessity scenarios
- switching marketing language toward “custom” blends or alternate forms
- drifting toward the less-policed edges of the internet (“research” peptides)
None of these moves automatically makes a product unsafe. The point is simpler: patients should expect more variability in what they are being offered—and more pressure to accept less transparency.
May 22, 2025
FDA’s semaglutide compounding phase-out included a specific enforcement-discretion date for 503B facilities, signaling when “business as usual” becomes legally risky (fda.gov).
Enforcement goes mainstream: warning letters, online claims, and dosing errors
The federal crackdown has not been subtle. The FDA has built a public record—safety pages, alerts, and warning letters—designed to puncture the idea that “unapproved GLP‑1” is a harmless shortcut.
The FDA’s standing concerns page
The agency maintains a consumer/provider explainer on unapproved GLP‑1 drugs used for weight loss, noting that it monitors online marketing and issues warning letters when it sees misleading claims.
Source: FDA’s concerns about unapproved GLP‑1 drugs used for weight loss (fda.gov).
That framework matters because much of the gray market is marketing. The promise is often equivalence: same effect, easier access, lower cost. Regulators are signaling that implied equivalence can cross legal lines, especially when sellers blur the distinction between FDA‑approved products and unapproved compounded or non-pharmacy sources.
Source: FDA’s concerns about unapproved GLP‑1 drugs used for weight loss (fda.gov).
That framework matters because much of the gray market is marketing. The promise is often equivalence: same effect, easier access, lower cost. Regulators are signaling that implied equivalence can cross legal lines, especially when sellers blur the distinction between FDA‑approved products and unapproved compounded or non-pharmacy sources.
Example: September 9, 2025 warning letters
One concrete datapoint: FDA warning letters dated September 9, 2025 targeted websites making misleading claims about compounded semaglutide/tirzepatide, including implications that their products were equivalent to FDA‑approved drugs.
Source: FDA warning letter example (“Slendid,” 09/09/2025) (fda.gov).
The letters are not just punitive; they are educational artifacts. They show how language—“same as,” “equivalent,” “FDA approved,” “Ozempic/Wegovy-like”—becomes the evidence.
Source: FDA warning letter example (“Slendid,” 09/09/2025) (fda.gov).
The letters are not just punitive; they are educational artifacts. They show how language—“same as,” “equivalent,” “FDA approved,” “Ozempic/Wegovy-like”—becomes the evidence.
September 9, 2025
A clearly documented enforcement action: FDA issued warning letters tied to misleading compounded GLP‑1 claims, marking marketing as a frontline (fda.gov).
Dosing errors are a separate, persistent hazard
Even when a compounded GLP‑1 is prepared by a legitimate pharmacy, the FDA has highlighted dosing errors—often stemming from concentration confusion, mis-measured injections, or patient misunderstanding when products are dispensed in vials instead of standardized pens.
Source: FDA alerts on dosing errors associated with compounded GLP‑1 drugs (fda.gov).
That risk isn’t a moral judgment about compounding. It’s a practical warning: the farther a patient gets from standardized packaging, the more they rely on clear labeling, careful counseling, and consistent quality controls.
Source: FDA alerts on dosing errors associated with compounded GLP‑1 drugs (fda.gov).
That risk isn’t a moral judgment about compounding. It’s a practical warning: the farther a patient gets from standardized packaging, the more they rely on clear labeling, careful counseling, and consistent quality controls.
Counterfeit vs. compounded vs. “research peptides”: a taxonomy of risk
Public debate collapses very different products into one scary category. Patients deserve a cleaner map. The FDA’s messaging helps draw it.
Counterfeit Ozempic: brand impersonation
Counterfeit products aim to look like the brand. On April 14, 2025, the FDA warned consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain.
Source: FDA warning about counterfeit Ozempic found in the U.S. supply chain (fda.gov).
A counterfeit is not “unapproved.” It’s fraudulent by design—an attempt to pass as an authentic manufacturer product. The risks range from wrong dose to unknown ingredients to contamination.
Source: FDA warning about counterfeit Ozempic found in the U.S. supply chain (fda.gov).
A counterfeit is not “unapproved.” It’s fraudulent by design—an attempt to pass as an authentic manufacturer product. The risks range from wrong dose to unknown ingredients to contamination.
April 14, 2025
FDA warned consumers not to use counterfeit Ozempic found in the U.S. supply chain—evidence counterfeit risk isn’t limited to shady websites (fda.gov).
Compounded GLP‑1s: legally bounded, not FDA‑approved
Compounded GLP‑1s occupy a different category. They may be prepared by licensed pharmacies or outsourcing facilities, but they are not FDA‑approved and do not get FDA premarket review for safety, quality, or effectiveness.
Source: FDA compounding safety communications (fda.gov).
In a shortage, enforcement discretion widened access. As shortages resolve, that discretion shrinks. The legal question becomes sharper: is there a patient-specific need that cannot be met by an FDA‑approved product?
Source: FDA compounding safety communications (fda.gov).
In a shortage, enforcement discretion widened access. As shortages resolve, that discretion shrinks. The legal question becomes sharper: is there a patient-specific need that cannot be met by an FDA‑approved product?
“Research use only” peptides: the least accountable category
Then there are products sold as research chemicals—often powders or vials marketed with a wink and a disclaimer. The gray market thrives on that ambiguity. The label says “not for human use,” while the marketing ecosystem—forums, influencers, telehealth-adjacent guidance—suggests the opposite.
For readers, the taxonomy offers a basic rule: the farther the product is from regulated pharmacy channels and standardized labeling, the more you’re forced to trust a seller’s promises rather than verifiable oversight.
For readers, the taxonomy offers a basic rule: the farther the product is from regulated pharmacy channels and standardized labeling, the more you’re forced to trust a seller’s promises rather than verifiable oversight.
Corporate pressure changes the market: lawsuits and supply-chain warnings
Federal policy is one lever. Corporate legal pressure is another. As GLP‑1 revenue became one of the defining pharmaceutical stories of the decade, manufacturers moved aggressively to protect their products and brands.
Eli Lilly’s lawsuits over “alternative” tirzepatide
NPR reported that Eli Lilly filed lawsuits (April 23, 2025) against entities selling “alternative versions” of tirzepatide, arguing that mass compounding becomes illegal and deceptive when it is not justified by shortage or medical necessity.
Source: NPR reporting on Eli Lilly lawsuits (npr.org).
From a patient perspective, lawsuits can look like pure profit protection. From a regulatory perspective, they also function as private enforcement: manufacturers have the incentives and resources to pursue sellers faster than the government can.
Source: NPR reporting on Eli Lilly lawsuits (npr.org).
From a patient perspective, lawsuits can look like pure profit protection. From a regulatory perspective, they also function as private enforcement: manufacturers have the incentives and resources to pursue sellers faster than the government can.
April 23, 2025
NPR reported Eli Lilly’s lawsuits over “alternative versions” of tirzepatide—another date-stamped marker that mass-market “alternatives” entered a high-risk zone.
Novo Nordisk and counterfeit warnings
Novo Nordisk has publicly warned about counterfeit Ozempic units in the U.S. supply chain. The FDA’s counterfeit alert underscores that counterfeit risk is not hypothetical.
Source: FDA counterfeit Ozempic warning (fda.gov).
Source: FDA counterfeit Ozempic warning (fda.gov).
Telehealth drama as a market temperature check
An Associated Press report described Novo’s threat to sue around an “off-brand/knockoff” semaglutide pill initiative and subsequent shifts in posture. Regardless of the corporate specifics, the takeaway is that enforcement risk is shaping behavior across the GLP‑1 ecosystem, including telehealth companies that once marketed access as frictionless.
Source: AP coverage (apnews.com).
Multiple perspectives matter here. Patients argue—often reasonably—that access and affordability failures created the gray market. Manufacturers argue—often reasonably—that uncontrolled versions threaten safety and trust. Regulators are trying to draw lines that protect patients without freezing access for those who can’t afford brand pricing.
Source: AP coverage (apnews.com).
Multiple perspectives matter here. Patients argue—often reasonably—that access and affordability failures created the gray market. Manufacturers argue—often reasonably—that uncontrolled versions threaten safety and trust. Regulators are trying to draw lines that protect patients without freezing access for those who can’t afford brand pricing.
The post-crackdown pivot: how sellers adapt when “copycat” gets risky
Regulatory tightening doesn’t remove demand. It reshapes supply. As enforcement discretion sunsets and warning letters proliferate, sellers adapt—sometimes in ways that make it harder for patients to know what they’re buying.
The “personalization” pitch
One common pivot is language: “custom,” “tailored,” “clinician-designed,” “with B12.” Additives can be clinically appropriate in some contexts, but they can also serve a marketing purpose—creating distance from the branded drug’s identity while keeping the promise of similar outcomes.
Alternative forms and new peptides
Another pivot is form factor: different delivery methods or products described as “like semaglutide” rather than semaglutide itself. The goal is to stay one step ahead of a regulatory framework designed around known molecules and shortage-driven compounding exceptions.
Why patients should be wary of ambiguity, not just illegality
Some readers hear “gray market” and assume criminals in warehouses. The more common reality can be professionally designed websites, polished telehealth portals, and clinic-grade branding. The risk isn’t always that the product is fake. The risk is that the chain of custody, testing, and accountability becomes difficult to verify.
Practical implications for readers:
- Expect less open advertising of “compounded semaglutide/tirzepatide” as supply stabilizes and policy tightens.
- Expect more euphemisms and “membership” models that frame drug access as a service.
- Expect greater variability in concentration, packaging, and instructions—conditions that can increase dosing errors if counseling is inadequate.
Practical implications for readers:
- Expect less open advertising of “compounded semaglutide/tirzepatide” as supply stabilizes and policy tightens.
- Expect more euphemisms and “membership” models that frame drug access as a service.
- Expect greater variability in concentration, packaging, and instructions—conditions that can increase dosing errors if counseling is inadequate.
How to protect yourself: questions patients should ask before taking any GLP‑1 outside the brand channel
Readers deserve more than warnings. They deserve a checklist that respects the complexity: compounding can be legitimate, counterfeit products can infiltrate supply chains, and online “research” vials can be catastrophically opaque.
A patient’s verification checklist
Ask direct questions and insist on clear answers:
Verification checklist
- ✓What is the exact active ingredient and concentration? Request the label details in writing.
- ✓Where is it dispensed from? Is a licensed pharmacy involved, and which one?
- ✓Is it a compounded drug? If yes, why is compounding needed for you specifically?
- ✓What form is it in—pen or vial? If vial, ask for dosing education to reduce error risk.
- ✓Are you being told it’s “equivalent” to a brand drug? Be cautious: FDA warning letters show that implied equivalence is a regulatory trigger.
Red flags that warrant walking away
Red flags
- ✓“Research use only” products marketed for self-injection
- ✓Claims that the product is “FDA approved” when it is compounded
- ✓Vague sourcing (“European pharmacy,” “lab-grade”) with no pharmacy accountability
- ✓Pressure tactics: “limited supply,” “buy three months now,” “prices rise tomorrow”
A fair note on why people take the risk
Many patients moved toward compounded or alternative supply because brand products were hard to find or hard to afford. That reality deserves acknowledgment. A system that makes high-demand obesity and diabetes drugs inaccessible will always generate a work-around economy.
The FDA’s position, though, is not subtle: compounded products are not FDA‑approved, and unapproved GLP‑1 marketing is under active scrutiny. The safest path is boring—licensed prescribers, regulated pharmacies, transparent labeling, and careful dosing education.
The FDA’s position, though, is not subtle: compounded products are not FDA‑approved, and unapproved GLP‑1 marketing is under active scrutiny. The safest path is boring—licensed prescribers, regulated pharmacies, transparent labeling, and careful dosing education.
“When the market gets more confusing, the smartest move is to demand clarity—about ingredient, dose, and accountability.”
— — TheMurrow Editorial
Conclusion: the GLP‑1 boom’s next chapter is about trust
The early GLP‑1 boom was powered by demand and cultural momentum. The next chapter is powered by enforcement, lawsuits, and the slow reassertion of rules that were temporarily loosened by shortage.
As the FDA phases out enforcement discretion—ending it for 503A in the relevant period and setting May 22, 2025 as a key date for 503B—mass-market “copycat” compounding becomes harder to defend. Warning letters dated September 9, 2025 show that regulators are also policing the story sellers tell, not just the substances they ship. And counterfeit alerts like April 14, 2025 remind patients that brand impersonation can penetrate real supply channels.
None of this eliminates the basic problem: millions of people want effective weight-loss and metabolic drugs, and many can’t access them easily. The gray market grew fast for human reasons. It will shrink—then re-form—unless affordability and availability improve inside the regulated system.
For readers, the non-negotiable is accountability. If a seller can’t clearly explain what’s in the vial, where it came from, and why you need that version, the risk isn’t only medical. It’s epistemic. You’re being asked to inject uncertainty.
As the FDA phases out enforcement discretion—ending it for 503A in the relevant period and setting May 22, 2025 as a key date for 503B—mass-market “copycat” compounding becomes harder to defend. Warning letters dated September 9, 2025 show that regulators are also policing the story sellers tell, not just the substances they ship. And counterfeit alerts like April 14, 2025 remind patients that brand impersonation can penetrate real supply channels.
None of this eliminates the basic problem: millions of people want effective weight-loss and metabolic drugs, and many can’t access them easily. The gray market grew fast for human reasons. It will shrink—then re-form—unless affordability and availability improve inside the regulated system.
For readers, the non-negotiable is accountability. If a seller can’t clearly explain what’s in the vial, where it came from, and why you need that version, the risk isn’t only medical. It’s epistemic. You’re being asked to inject uncertainty.
1) What exactly is the “GLP‑1 gray market”?
The GLP‑1 gray market refers to overlapping channels selling semaglutide, tirzepatide, or related peptides outside the standard FDA‑approved distribution pathway. It includes some compounding-adjacent services, med-spa injections marketed as “Ozempic-like,” and online “research use only” vials. The defining feature is ambiguity—about sourcing, oversight, and whether the product is being marketed as equivalent to FDA‑approved drugs.
2) Are compounded semaglutide and tirzepatide FDA‑approved?
No. The FDA stresses that compounded drugs are not FDA‑approved and do not undergo FDA premarket review for safety, quality, or effectiveness. Compounded drugs can be legal in limited circumstances, but they are still different from FDA‑approved products. FDA has also highlighted dosing errors associated with compounded GLP‑1 formulations, particularly when products are dispensed in vials with variable concentrations.
3) Why is access to compounded GLP‑1s shrinking now?
FDA policy has shifted as national supply stabilizes. FDA stated that tirzepatide injection shortage was resolved and described a phase-out approach for semaglutide injection products, including that enforcement discretion for 503A ended in the relevant period and that 503B discretion lasted until May 22, 2025. As those conditions tighten, high-volume “copycat” compounding becomes harder to justify without patient-specific medical necessity.
4) What’s the difference between counterfeit Ozempic and compounded semaglutide?
Counterfeit Ozempic is brand impersonation—fraudulent products designed to look like Novo Nordisk’s real Ozempic. On April 14, 2025, FDA warned consumers not to use counterfeit Ozempic found in the U.S. supply chain. Compounded semaglutide
T
About the Author
TheMurrow Editorial is a writer for TheMurrow covering health & wellness.
Frequently Asked Questions
What exactly is the “GLP‑1 gray market”?
The GLP‑1 gray market refers to overlapping channels selling semaglutide, tirzepatide, or related peptides outside the standard FDA‑approved distribution pathway. It includes some compounding-adjacent services, med-spa injections marketed as “Ozempic-like,” and online “research use only” vials. The defining feature is ambiguity—about sourcing, oversight, and whether the product is being marketed as equivalent to FDA‑approved drugs.
Are compounded semaglutide and tirzepatide FDA‑approved?
No. The FDA stresses that compounded drugs are not FDA‑approved and do not undergo FDA premarket review for safety, quality, or effectiveness. Compounded drugs can be legal in limited circumstances, but they are still different from FDA‑approved products. FDA has also highlighted dosing errors associated with compounded GLP‑1 formulations, particularly when products are dispensed in vials with variable concentrations.
Why is access to compounded GLP‑1s shrinking now?
FDA policy has shifted as national supply stabilizes. FDA stated that tirzepatide injection shortage was resolved and described a phase-out approach for semaglutide injection products, including that enforcement discretion for 503A ended in the relevant period and that 503B discretion lasted until May 22, 2025. As those conditions tighten, high-volume “copycat” compounding becomes harder to justify without patient-specific medical necessity.
What’s the difference between counterfeit Ozempic and compounded semaglutide?
Counterfeit Ozempic is brand impersonation—fraudulent products designed to look like Novo Nordisk’s real Ozempic. On April 14, 2025, FDA warned consumers not to use counterfeit Ozempic found in the U.S. supply chain. Compounded semaglutide
